Patents by Inventor Barbara HERKERT

Barbara HERKERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azepane inhibitors of menin-MLL interaction
    Patent number: 11530226
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Spiro Bicyclic Inhibitors Of Menin-MLL Interaction
    Publication number: 20220227786
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: November 29, 2021
    Publication date: July 21, 2022
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Spiro bicyclic inhibitors of menin-MLL interaction
    Patent number: 11220517
    Abstract: The present invention relates to compounds of formula (I): wherein the variables have the meaning defined in the Specification. The compounds according to the present invention are useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: January 11, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20210122757
    Abstract: The present invention relates to novel spirocyclic compounds which act as modulators of indoleaine 2,3-dioxygenase (IDO1) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dioxygenase. The invention further relates to pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 29, 2021
    Inventors: Olaf KINZEL, Christoph STEENECK, Simon ANDERHUB, Martin HORNBERGER, Sheena PINTO, Barbara HERKERT, Thomas HOFFMANN
  • Fused bicyclic inhibitors of menin-MLL interaction
    Patent number: 10975100
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick
  • Azepane Inhibitors Of Menin-MLL Interaction
    Publication number: 20200339594
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 29, 2020
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • Azepane inhibitors of menin-MLL interaction
    Patent number: 10745409
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noëlle Constance Pilatte
  • FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20200172556
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 4, 2020
    Inventors: Patrick Rene ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK
  • Fused bicyclic inhibitors of menin-MLL interaction
    Patent number: 10611778
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick
  • AZEPANE INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20190322685
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 24, 2019
    Inventors: Patrick René ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK, Isabelle Noëlle Constance PILATTE
  • FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20190218230
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 18, 2019
    Applicant: Janssen Pharmaceultica nv
    Inventors: Patrick Rene ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK
  • SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20190211036
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 11, 2019
    Inventors: Patrick Rene ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK, Isabelle Noelle Constance PILATTE